- Investor's Business Daily•7 minutes ago
A California ballot initiative requiring the state's Medicaid arm to buy drugs at comparable prices to what the VA pays could backfire, RBC says.
- American City Business Journals•8 hours ago
On Wednesday evening, Vertex Pharmaceuticals lowered full-year revenue predictions for its newest cystic fibrosis drug, effectively confirming fears investors first had a couple of weeks ago following comments by Vertex executives at a conference. While announcing the news that the U.S. Food and Drug Administration has approved Orkambi for use in patients ages 6-11 (it was previously able to be used in patients 12 and up), Vertex (VRTX) officials said the company now expects sales of the drug in 2016 to come in between $950 million and $990 million.
- Reuters•21 hours ago
Vertex Pharamceuticals Inc said the U.S. Food and Drug Administration expanded the use of its cystic fibrosis drug to treat a new subgroup of patients with the rare genetic disorder. The FDA approved the use of Orkambi in children with cystic fibrosis aged 6-11 who have a type of the mutation. Cystic fibrosis is a life-threatening condition, where a defective gene disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections.
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||86.15 x 200|
|Ask||86.21 x 100|
|Day's Range||85.25 - 90.77|
|52wk Range||75.90 - 134.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-75.68|
|Avg Vol (3m)||1,336,589|
|Dividend & Yield||N/A (N/A)|